- 7/24 Live Call Center
A step-by-step guide to Pancreatic Cancer Procedure steps, including imaging, endoscopic ultrasound, and biopsy methods for accurate diagnosis and staging.
Send us all your questions or requests, and our expert team will assist you.
The diagnostic process for pancreatic cancer is a meticulous integration of clinical history, biochemical data, and advanced imaging. Because the pancreas is inaccessible to physical palpation, physicians rely heavily on technology to visualize the organ. The journey typically begins when a patient presents with symptoms such as jaundice or abdominal pain. The initial step usually involves blood tests to evaluate liver function. Elevated bilirubin and liver enzymes can suggest biliary obstruction, suggesting a pancreatic head mass.
Following biochemical analysis, medical imaging is the cornerstone of diagnosis. A multiphasic Computed Tomography (CT) scan with a specific pancreatic protocol is the standard first-line modality. This involves capturing images at precisely timed intervals after the injection of contrast dye. This technique allows radiologists to visualize the relationship between the tumor and critical blood vessels, such as the superior mesenteric artery and portal vein. This relationship is the primary determinant of whether a tumor can be surgically removed.
If a CT scan is inconclusive or if further characterization is needed, Magnetic Resonance Imaging (MRI) with Magnetic Resonance Cholangiopancreatography (MRCP) may be utilized. MRCP provides detailed visualization of the pancreatic and bile ducts without the need for invasive instrumentation. It is beneficial for evaluating cystic lesions and defining the anatomy of the ductal system. Positron Emission Tomography (PET-CT) is also employed, using a radioactive glucose tracer to identify areas of high metabolic activity, which helps in detecting distant metastases that might not be visible on a standard CT scan.
While imaging provides a roadmap, a definitive diagnosis of cancer requires examining cells under a microscope. Obtaining a tissue sample from the pancreas is complex due to its deep anatomical location. The preferred method for obtaining a biopsy is Endoscopic Ultrasound (EUS). In this procedure, a specialized endoscope with an ultrasound probe at its tip is passed down the esophagus into the stomach and duodenum. This allows the physician to place the ultrasound transducer directly adjacent to the pancreas, providing high-resolution images.
Through the EUS scope, a thin needle can be precisely guided into the suspicious mass to aspirate cells (Fine Needle Aspiration, FNA) or remove a core of tissue (Fine Needle Biopsy, FNB). This minimally invasive approach avoids the need for percutaneous biopsy through the skin, which carries a risk of tumor seeding. The collected cells are then analyzed by a pathologist to confirm the presence of malignant cells and to determine the specific histological type, distinguishing between adenocarcinoma and neuroendocrine tumors.
In some instances, a biopsy may not be performed before surgery. If a mass looks like cancer on imaging and appears surgically removable, the medical team may opt to proceed directly to surgery to remove the tumor, performing the biopsy on the resected specimen. This decision is made to avoid any delay in curative treatment. However, if chemotherapy is planned before surgery (neoadjuvant therapy) or if the disease is metastatic, a biopsy is mandatory to guide the choice of systemic treatment.
In addition to imaging and biopsy, specific blood markers support the management of pancreatic cancer. The most commonly used tumor marker is Carbohydrate Antigen 19-9 (CA 19-9). CA 19-9 is a protein shed from the surface of cancer cells. While elevated levels can indicate pancreatic cancer, it is not a perfect screening tool because benign conditions like gallstones or pancreatitis can also cause elevations. Furthermore, some individuals genetically do not produce CA 19-9, rendering the test negative even in the presence of cancer.
Despite these limitations, CA 19-9 is valuable for establishing a baseline before treatment. If levels are high at diagnosis and drop after surgery or chemotherapy, it indicates a treatment response. Conversely, rising levels during surveillance may signal a recurrence before it is visible on scans. Carcinoembryonic Antigen (CEA) is another marker sometimes checked, though it is less specific for pancreatic issues.
Advancements in molecular pathology now allow testing of tumor tissue for specific genetic mutations. This is known as somatic genomic testing. Identifying mutations in genes such as KRAS, BRCA, and Mismatch Repair (MMR) genes can open the door to targeted therapies and immunotherapies. This molecular profiling is becoming a standard part of the diagnostic workup, moving diagnosis beyond just naming the cancer to understanding its biological drivers.
Staging is the process of determining the extent of the disease, which directly dictates the treatment strategy. The TNM system (Tumor, Node, Metastasis) is the standard for anatomical staging. “T” describes the size and extent of the primary tumor, “N” indicates if cancer has spread to nearby lymph nodes, and “M” denotes the presence of metastasis to distant organs. However, in clinical practice, pancreatic cancer is often grouped into functional categories based on resectability—the ability to be surgically removed.
Resectable: The tumor is confined to the pancreas and does not contact major blood vessels, or the contact is minimal. Surgery is the primary treatment option.
Borderline Resectable: The tumor contacts major blood vessels (veins or arteries), but may still be resectable. These patients typically receive chemotherapy and/or radiation first (neoadjuvant therapy) to shrink the tumor away from the vessels before attempting surgery.
Locally Advanced: The tumor encases major blood vessels significantly and cannot be removed surgically without a high risk or leaving cancer behind. Treatment focuses on systemic chemotherapy and radiation to control growth.
Metastatic: The cancer has spread to distant organs such as the liver, lungs, or peritoneum. Surgery to remove the primary pancreatic tumor is generally not performed, and treatment focuses on systemic chemotherapy to extend life and manage symptoms.
This clinical staging is fluid; a patient with borderline resectable disease may become resectable after successful neoadjuvant therapy. Conversely, a patient thought to be resectable may be found to have small metastases during the initial steps of surgery, changing the stage to metastatic.
Send us all your questions or requests, and our expert team will assist you.
Clinical staging is an estimate of the extent of the cancer based on physical exams, imaging scans (CT, MRI), and biopsies performed before any primary treatment. Pathological staging is determined after surgery, when a pathologist examines the removed tumor and lymph nodes under a microscope, providing the most accurate assessment of the cancer’s spread.
In some cases, tiny metastases in the liver or the lining of the abdomen (peritoneum) are too small to be seen on CT scans. A surgeon may perform a diagnostic laparoscopy, inserting a camera into the abdomen through a small cut, to visually inspect these areas and ensure the cancer has not spread before proceeding with a major removal operation.
No, there is currently no blood test that can diagnose pancreatic cancer on its own. While markers like CA 19-9 can be elevated in cancer patients, they can also be high in non-cancerous conditions. A diagnosis always requires imaging and, for confirmation, usually a tissue biopsy.
Vascular encasement means the tumor has grown around a blood vessel, forming a cuff-like structure. If the cancer surrounds a major artery or vein significantly (usually more than 180 degrees), it makes surgical removal extremely difficult or impossible because the vessel cannot be safely separated from the tumor without cutting off blood supply to vital organs.
Not always. A high-quality CT scan is the standard for diagnosis. However, PET-CT is beneficial in ambiguous cases to distinguish between scar tissue and active tumor, or to detect hidden distant metastases that might change the treatment plan from surgery to systemic therapy.
Almost 90% of cancer-related deaths result from metastatic disease, which happens when cancer spreads from its original site to other parts of the body. Understanding
Nearly 1 in 5 cancer patients see their cancer come back, often because the cancer has spread without being caught early. This makes it crucial
Your Comparison List (you must select at least 2 packages)
